| Early clinical predictors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after myeloablative stem cell transplantation LE Roeker, HT Kim, B Glotzbecker, P Nageshwar, S Nikiforow, J Koreth, ... Biology of Blood and Marrow Transplantation 25 (1), 137-144, 2019 | 45 | 2019 |
| Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease N Kekre, HT Kim, J Hofer, VT Ho, J Koreth, P Armand, S Nikiforow, ... Bone marrow transplantation 56 (5), 1006-1012, 2021 | 28* | 2021 |
| A comparison of the myeloablative conditioning regimen fludarabine/busulfan with cyclophosphamide/total body irradiation, for allogeneic stem cell transplantation in the modern … M Gooptu, HT Kim, VT Ho, EP Alyea, J Koreth, P Armand, J Ritz, ... Biology of Blood and Marrow Transplantation 24 (8), 1733-1740, 2018 | 27 | 2018 |
| Incidence, predictors, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome after reduced-intensity allogeneic hematopoietic cell transplantation C Lewis, HT Kim, LE Roeker, C Cutler, J Koreth, S Nikiforow, P Armand, ... Biology of Blood and Marrow Transplantation 26 (3), 529-539, 2020 | 16 | 2020 |
| Phase II trial of natalizumab (Tysabri®) with corticosteroids as initial treatment of gastrointestinal acute graft versus host disease N Kekre, HT Kim, VT Ho, Y Guo, U Mahmood, W Belatreche, J Koreth, ... Blood 130, 3252, 2017 | 4 | 2017 |
| Phase II trial of natalizumab (Tysabri (R)) with corticosteroids as initial treatment of gastrointestinal acute graft versus host disease N Kekre, HT Kim, VT Ho, Y Guo, U Mahmood, W Belatreche, J Koreth, ... Biology of Blood and Marrow Transplantation 24 (3), S69-S69, 2018 | 1 | 2018 |
| Donor Source and Gvhd Prophylaxis Impact Risk of Acute Renal Injury in the Peri-Engraftment Period after Allogeneic Stem Cell Transplantation JA Vergara-Cadavid, PC Johnson, VT Ho, D Cirstea, P Nageshwar, ... 2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2022 | | 2022 |
| Cytokine Release Syndrome Post HLA-Mismatched Stem Cell Transplantation Does Not Affect Immune Reconstitution and Is Effectively Treated with Tocilizumab RM Shapiro, K Baker, C Reynolds, HT Kim, S Nikiforow, D Cirstea, ... 2022 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2022 | | 2022 |
| Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease N Kekre, HT Kim, J Hofer, VT Ho, J Koreth, P Armand, S Nikiforow, ... Bone marrow transplantation 56 (5), 1217, 2021 | | 2021 |
| Management of Cytokine Release Syndrome U Acharya, AEC Daylan, P Nageshwar Handbook of Stem Cell Transplantation and Cellular Therapy Management, 263, 2020 | | 2020 |
| Handbook of stem cell transplantation and cellular therapy management EP Alyea III, VT Ho, BE Glotzbecker, P Nageshwar Springer Publishing Company, 2020 | | 2020 |
| Incidence and Predictors of Hepatic Veno-Occlusive Disease after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation C Lewis, HT Kim, CS Cutler, J Koreth, S Nikiforow, M Gooptu, R Romee, ... Blood 132, 3376, 2018 | | 2018 |
